NextCure, Inc.

Equities

NXTC

US65343E1082

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
1.67 ^USD	+1.21%		-2.91%	+46.49%

May. 02	NextCure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 08	NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024	CI

NextCure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 02, 2024 at 04:21 pm EDT

NextCure, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 17.11 million compared to USD 16.1 million a year ago. Basic loss per share from continuing operations was USD 0.61 compared to USD 0.58 a year ago.

Diluted loss per share from continuing operations was USD 0.61 compared to USD 0.58 a year ago.

Latest news about NextCure, Inc.

NextCure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024	Apr. 08	CI
NextCure, Inc. Appoints Rakesh Dixit to Scientific Advisory Board	Apr. 04	CI
NextCure, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
North American Morning Briefing : Markets on Hold -2-	Mar. 20	DJ
Top Premarket Decliners	Feb. 27	MT
NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders	Jan. 18	CI
Nextcure, Inc. Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury	Dec. 21	CI
Nextcure, Inc. Provides Year-End Clinical Pipeline Updates	Dec. 14	CI
NextCure, Inc. Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML	Nov. 15	CI
NextCure, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
NextCure, Inc. Announces Presentation of New Preclinical Data Demonstrate Treatment with NC605	23-10-17	CI
NextCure Says Preclinical Data of NC181 for Alzheimer's Disease Shows Amyloid Clearance	23-09-26	MT
NextCure, Inc. Presents Preclinical Data on Nc181, A Novel Therapeutic Candidate Targeting Apoe4, for the Treatment of Alzheimer's Disease	23-09-26	CI
NextCure, Inc.(NasdaqGS:NXTC) dropped from S&P Global BMI Index	23-09-18	CI
NextCure Reports Preclinical Data Show Potential NC605 Application in Bone Disease Treatment	23-09-05	MT
HC Wainwright Initiates NextCure With Buy Rating, $7 Price Target	23-08-08	MT
NextCure, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
NextCure, Inc. Announces Resignation of Garry A. Nicholson as from the Board of Directors	23-07-19	CI
NextCure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
NextCure, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-02	CI
NextCure, Inc.(NasdaqGS:NXTC) dropped from NASDAQ Biotechnology Index	22-12-16	CI
Transcript : NextCure, Inc. Presents at Bank of America 2022 Virtual Biotech SMID Cap Conference, Dec-08-2022 03:20 PM	22-12-08
NextCure, LegoChem Biosciences to Collaborate on Development of Antibody Drug Conjugates	22-11-16	MT
NextCure, Inc. and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates	22-11-15	CI

Chart NextCure, Inc.

Duration

Period

More charts

Company Profile

NextCure, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including Antibody-Drug Conjugates (ADCs), antibodies, and proteins. The Company focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidates include NC410 and LNCB74. Its Clinical Oncology Programs are NC525 and NC318. Its Pre-Clinical Non-Oncology Programs are NC605 and NC181. NC410 is a LAIR-2 fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers. NCB74 is an ADC that is directed to B7-H4, a clinically validated cancer target.

Sector

Biotechnology & Medical Research

Calendar

2024-06-01 - American Society of Clinical Oncology Annual Meeting - Abstract Number: 2538

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.65 USD

Average target price

5 USD

Spread / Average Target

+203.03%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NEXTCURE, INC.	+46.49%	46.16M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	114B
REGENERON PHARMACEUTICALS, INC.	+11.84%	104B
BIONTECH SE	-14.15%	22.41B
ARGENX SE	-1.05%	22.28B
GENMAB A/S	-5.29%	19.07B
WUXI APPTEC CO., LTD.	-38.29%	18B
BEIGENE, LTD.	-4.16%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.28B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.55B

Bio Therapeutic Drugs